144 related articles for article (PubMed ID: 35421703)
1. Treatment response and 5-year distant metastasis-free survival outcome in breast cancer patients after the use of MammaPrint and BluePrint to guide preoperative systemic treatment decisions.
Göker E; Hendriks MP; van Tilburg M; Barcaru A; Mittempergher L; van Egmond A; Kleijn M; Generali D;
Eur J Cancer; 2022 May; 167():92-102. PubMed ID: 35421703
[TBL] [Abstract][Full Text] [Related]
2. Chemosensitivity predicted by BluePrint 80-gene functional subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST).
Whitworth P; Stork-Sloots L; de Snoo FA; Richards P; Rotkis M; Beatty J; Mislowsky A; Pellicane JV; Nguyen B; Lee L; Nash C; Gittleman M; Akbari S; Beitsch PD
Ann Surg Oncol; 2014 Oct; 21(10):3261-7. PubMed ID: 25099655
[TBL] [Abstract][Full Text] [Related]
3. Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping.
Whitworth P; Beitsch P; Mislowsky A; Pellicane JV; Nash C; Murray M; Lee LA; Dul CL; Rotkis M; Baron P; Stork-Sloots L; de Snoo FA; Beatty J
Ann Surg Oncol; 2017 Mar; 24(3):669-675. PubMed ID: 27770345
[TBL] [Abstract][Full Text] [Related]
4. Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy.
Glück S; de Snoo F; Peeters J; Stork-Sloots L; Somlo G
Breast Cancer Res Treat; 2013 Jun; 139(3):759-67. PubMed ID: 23756626
[TBL] [Abstract][Full Text] [Related]
5. Molecular subtyping predicts pathologic tumor response in early-stage breast cancer treated with neoadjuvant docetaxel plus capecitabine with or without trastuzumab chemotherapy.
Bayraktar S; Royce M; Stork-Sloots L; de Snoo F; Glück S
Med Oncol; 2014 Oct; 31(10):163. PubMed ID: 25186065
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical versus molecular (BluePrint and MammaPrint) subtyping of breast carcinoma. Outcome results from the EORTC 10041/BIG 3-04 MINDACT trial.
Viale G; de Snoo FA; Slaets L; Bogaerts J; van 't Veer L; Rutgers EJ; Piccart-Gebhart MJ; Stork-Sloots L; Glas A; Russo L; Dell'Orto P; Tryfonidis K; Litière S; Cardoso F;
Breast Cancer Res Treat; 2018 Jan; 167(1):123-131. PubMed ID: 28929359
[TBL] [Abstract][Full Text] [Related]
7. Genomic profiling of breast cancer in African-American women using MammaPrint.
Nunes RA; Wray L; Mete M; Herbolsheimer P; Smith KL; Bijelic L; Boisvert ME; Swain SM
Breast Cancer Res Treat; 2016 Oct; 159(3):481-8. PubMed ID: 27568021
[TBL] [Abstract][Full Text] [Related]
8. Comparison of molecular subtyping with BluePrint, MammaPrint, and TargetPrint to local clinical subtyping in breast cancer patients.
Nguyen B; Cusumano PG; Deck K; Kerlin D; Garcia AA; Barone JL; Rivera E; Yao K; de Snoo FA; van den Akker J; Stork-Sloots L; Generali D
Ann Surg Oncol; 2012 Oct; 19(10):3257-63. PubMed ID: 22965266
[TBL] [Abstract][Full Text] [Related]
9. Age-Independent Preoperative Chemosensitivity and 5-Year Outcome Determined by Combined 70- and 80-Gene Signature in a Prospective Trial in Early-Stage Breast Cancer.
Whitworth P; Beitsch PD; Pellicane JV; Baron PL; Lee LA; Dul CL; Nash CH; Murray MK; Richards PD; Gittleman M; Budway R; Rahman RL; Kelemen P; Dooley WC; Rock DT; Cowan K; Lesnikoski BA; Barone JL; Ashikari AY; Dupree B; Wang S; Menicucci AR; Yoder EB; Finn C; Corcoran K; Blumencranz LE; Audeh W;
Ann Surg Oncol; 2022 Apr; 29(7):4141-52. PubMed ID: 35378634
[TBL] [Abstract][Full Text] [Related]
10. Distinct Neoadjuvant Chemotherapy Response and 5-Year Outcome in Patients With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Tumors That Reclassify as Basal-Type by the 80-Gene Signature.
Whitworth PW; Beitsch PD; Pellicane JV; Baron PL; Lee LA; Dul CL; Murray MK; Gittleman MA; Budway RJ; Rahman RL; Kelemen PR; Dooley WC; Rock DT; Cowan KH; Lesnikoski BA; Barone JL; Ashikari AY; Dupree BB; Wang S; Menicucci AR; Yoder EB; Finn C; Corcoran K; Blumencranz LE; Audeh W;
JCO Precis Oncol; 2022 Apr; 6(1):e2100463. PubMed ID: 35476550
[TBL] [Abstract][Full Text] [Related]
11. Impact of Tumor Size on Probability of Pathologic Complete Response After Neoadjuvant Chemotherapy.
Baron P; Beitsch P; Boselli D; Symanowski J; Pellicane JV; Beatty J; Richards P; Mislowsky A; Nash C; Lee LA; Murray M; de Snoo FA; Stork-Sloots L; Gittleman M; Akbari S; Whitworth P
Ann Surg Oncol; 2016 May; 23(5):1522-9. PubMed ID: 26714960
[TBL] [Abstract][Full Text] [Related]
12. Molecular apocrine tumours in EORTC 10994/BIG 1-00 phase III study: pathological response after neoadjuvant chemotherapy and clinical outcomes.
Bonnefoi H; MacGrogan G; Poncet C; Iggo R; Pommeret F; Grellety T; Larsimont D; Bécette V; Kerdraon O; Bibeau F; Ghnassia JP; Picquenot JM; Thomas J; Tille JC; Slaets L; Bodmer A; Bergh J; Cameron D;
Br J Cancer; 2019 Apr; 120(9):913-921. PubMed ID: 30899086
[TBL] [Abstract][Full Text] [Related]
13. Pertuzumab/Trastuzumab/CT Versus Trastuzumab/CT Therapy for HER2+ Breast Cancer: Results from the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST).
Beitsch P; Whitworth P; Baron P; Rotkis MC; Mislowsky AM; Richards PD; Murray MK; Pellicane JV; Dul CL; Nash CH; Stork-Sloots L; de Snoo F; Untch S; Lee LA
Ann Surg Oncol; 2017 Sep; 24(9):2539-2546. PubMed ID: 28447218
[TBL] [Abstract][Full Text] [Related]
14. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials.
Denkert C; Seither F; Schneeweiss A; Link T; Blohmer JU; Just M; Wimberger P; Forberger A; Tesch H; Jackisch C; Schmatloch S; Reinisch M; Solomayer EF; Schmitt WD; Hanusch C; Fasching PA; Lübbe K; Solbach C; Huober J; Rhiem K; Marmé F; Reimer T; Schmidt M; Sinn BV; Janni W; Stickeler E; Michel L; Stötzer O; Hahnen E; Furlanetto J; Seiler S; Nekljudova V; Untch M; Loibl S
Lancet Oncol; 2021 Aug; 22(8):1151-1161. PubMed ID: 34252375
[TBL] [Abstract][Full Text] [Related]
15. The Predictive Utility of MammaPrint and BluePrint in Identifying Patients with Locally Advanced Breast Cancer Who are Most Likely to Have Nodal Downstaging and a Pathologic Complete Response After Neoadjuvant Chemotherapy.
Blumencranz P; Habibi M; Shivers S; Acs G; Blumencranz LE; Yoder EB; van der Baan B; Menicucci AR; Dauer P; Audeh W; Cox CE
Ann Surg Oncol; 2023 Dec; 30(13):8353-8361. PubMed ID: 37658272
[TBL] [Abstract][Full Text] [Related]
16. Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapy.
Du L; Yau C; Brown-Swigart L; Gould R; Krings G; Hirst GL; Bedrosian I; Layman RM; Carter JM; Klein M; Venters S; Shad S; van der Noordaa M; Chien AJ; Haddad T; Isaacs C; Pusztai L; Albain K; Nanda R; Tripathy D; Liu MC; Boughey J; Schwab R; Hylton N; DeMichele A; Perlmutter J; Yee D; Berry D; Van't Veer L; Valero V; Esserman LJ; Symmans WF
Ann Oncol; 2021 May; 32(5):642-651. PubMed ID: 33617937
[TBL] [Abstract][Full Text] [Related]
17. Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study.
Wuerstlein R; Kates R; Gluz O; Grischke EM; Schem C; Thill M; Hasmueller S; Köhler A; Otremba B; Griesinger F; Schindlbeck C; Trojan A; Otto F; Knauer M; Pusch R; Harbeck N;
Breast Cancer Res Treat; 2019 Jun; 175(2):389-399. PubMed ID: 30796651
[TBL] [Abstract][Full Text] [Related]
18. Molecular subtyping improves diagnostic stratification of patients with primary breast cancer into prognostically defined risk groups.
Yao K; Goldschmidt R; Turk M; Wesseling J; Stork-Sloots L; de Snoo F; Cristofanilli M
Breast Cancer Res Treat; 2015 Nov; 154(1):81-8. PubMed ID: 26424167
[TBL] [Abstract][Full Text] [Related]
19. Combined 70- and 80-gene signatures identify tumors with genomically luminal biology responsive to neoadjuvant endocrine therapy and are prognostic of 5-year outcome in early-stage breast cancer.
Pellicane JV; Beitsch PD; Rock DT; Budway RJ; Dul CL; Kelemen PR; Ashikari AY; Baron PL; Weinstein PD; Mislowsky A; Lee LA; Beatty J; Murray MK; Dupree BB; Finn C; Corcoran K; Wang S; Menicucci AR; Yoder EB; Blumencranz LE; Dauer P; Audeh W; Whitworth PW;
Surg Oncol; 2022 Dec; 45():101885. PubMed ID: 36436423
[TBL] [Abstract][Full Text] [Related]
20. Tumor Biology and Response to Chemotherapy Impact Breast Cancer-specific Survival in Node-positive Breast Cancer Patients Treated With Neoadjuvant Chemotherapy: Long-term Follow-up From ACOSOG Z1071 (Alliance).
Boughey JC; Ballman KV; McCall LM; Mittendorf EA; Symmans WF; Julian TB; Byrd D; Hunt KK
Ann Surg; 2017 Oct; 266(4):667-676. PubMed ID: 28657941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
